Stay updated with breaking news from Schedule M. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Under this scheme, pharma units can receive a maximum incentive of Rs 1 crore on an anticipated expense of Rs 150 crore. This will help the unit upgrade and meet the WHO GMP standards
Implementing the new GMP standard by 36 drug controllers in states and UTs is crucial, along with ensuring transparency and regulator accountability. India's trading partners, such as Gambia and Nigeria, have heightened scrutiny of Indian drug imports due to quality issues.
Union health minister Mansukh Mandaviya had announced last month that companies with a turnover of ₹250 crore and more will have to implement the revised GMP within six months. Medium and small-scale enterprises with a turnover of less than ₹250 crore will have to implement it within a year.
Bharat Serums and Vaccines Limited (BSV) is investing 200 crore to establish a speciality injectables manufacturing facility in Hyderabad's Genome Val
India's drug regulator, the Drug Controller General of India (DCGI), plans to review pharmaceutical manufacturing standards in order to ensure the quality, safety, and efficacy of drugs. The DCGI will meet with pharma industry associations to discuss reviewing Good Manufacturing Practices (GMP) for pharma companies. The government aims to upgrade Schedule M, which lays down GMP, to international standards.